As we previously reported, in a phase III trial (NEST; NCT01622361), conventional NCT yielded a significantly better response than NET in premenopausal patients with ER+/HER2-, LN+ breast cancer, supporting the ASCO and St. This evidence concerns the gene ERBB2 and breast carcinoma.